Table 22:
Budget Impact Sensitivity Analysis Population Parameters
| New Scenario | Parameter Used in Reference Case | Parameter Used in Scenario Analyses |
|---|---|---|
| Perspective | Ontario Ministry of Health | Societal (includes non-medical costs for outpatient clinic NB-UVB phototherapy) (See Appendix 7B for details) |
| Treatment pathway | 100% of those switching out of phototherapy would switch into topical therapy | Those switching out of phototherapy would switch to systemic non-biologic (16%), biologic (14%), or topical (70%) therapy (see Appendix 7B for details) |
| Percent population uptake | 5% uptake each year | Starting with 5% uptake in year 1, increase uptake 5% each year (i.e., 5% in year 1, 10% in year 2, etc.) |
| Proportion suitable for home NB-UVB | 50% | 25%; 75% |
| IntelliHealth assumption: those with unknown diagnosis | Include only those with known psoriasis diagnosis Annual number of people: 3,440 |
Also include a portion of people with unknown diagnosis (as reported in IntelliHealth) who may have a psoriasis diagnosis Annual number of people: 4,404a |
| Population | People with psoriasis | People with eczema (Appendix 7A); all photoresponsive conditions |
Abbreviation: NB-UVB, narrowband ultraviolet B phototherapy.
a
Based on data from 2011 to 2016. Phototherapy users diagnosed with psoriasis accounted for 50% of all users with known diagnosis. We applied this proportion to the number of phototherapy users with unspecified diagnosis (N = 1,935 per year) and assumed 50% of those people to be suitable for home phototherapy to calculate the additional number of people for the target population.